Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chongqing Genrix Biopharmaceutical Co's quarterly market cap
declined
from Sep. 2025 (¥11,202.1 Mil) to Dec. 2025 (¥9,988.4 Mil) and
declined
from Dec. 2025 (¥9,988.4 Mil) to Mar. 2026 (¥9,409.0 Mil).
Chongqing Genrix Biopharmaceutical Co's annual market cap
declined
from Dec. 2023 (¥14,648.9 Mil) to Dec. 2024 (¥9,200.0 Mil) but then
increased
from Dec. 2024 (¥9,200.0 Mil) to Dec. 2025 (¥9,988.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Chongqing Genrix Biopharmaceutical Co's Enterprise Value for Today is ¥8,006.8 Mil.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Chongqing Genrix Biopharmaceutical Co Market Cap Related Terms
Chongqing Genrix Biopharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co Market Cap Chart
SHSE:688443 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Genrix Biopharmaceutical Co Market Cap vs Biotechnology Industry
Chongqing Genrix Biopharmaceutical Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a Market Cap of ¥9,178.0 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. According to the industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #235 out of 1423 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Chongqing Genrix Biopharmaceutical Co's Market Cap too high?
Chongqing Genrix Biopharmaceutical Co's current Market Cap is ¥9,178.0 Mil. Based on the distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #235 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chongqing Genrix Biopharmaceutical Co has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Chongqing Genrix Biopharmaceutical Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #235 out of 1423 companies for Market Cap. This places Chongqing Genrix Biopharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.11, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Market Cap is 113.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Genrix Biopharmaceutical Co's current Market Cap is ¥9,178.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Genrix Biopharmaceutical Co stock overvalued right now?
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a current Market Cap of ¥9,178.0 Mil. The current Market Cap is ¥9,178.0 Mil. Chongqing Genrix Biopharmaceutical Co's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Chongqing Genrix Biopharmaceutical Co (SHSE:688443), the current Market Cap is ¥9,178.0 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chongqing Genrix Biopharmaceutical Co Business Description
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
43GF Score
Get the complete analysis for SHSE:688443
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688443 has been successfully added to your 
